Promega v. Aobious: Consent Judgment & Permanent Injunction in NanoLuc Substrate Dispute
Promega Corporation secured a consent judgment and permanent injunction against Aobious Inc. in the Delaware District Court, finding infringement of four patents covering furimazine, hydrofurimazine, and fluorofurimazine luciferase substrates central to the Nano-Glo® product platform. The case resolved in just 134 days from filing — a signal of early settlement pressure and strong patent position.
Promega locks down NanoLuc substrate IP with swift consent judgment
On 3 March 2025, Promega Corporation filed suit in the Delaware District Court against Aobious Inc., asserting infringement of four US patents — US8,809,529, US10,000,500, US10,669,280, and US11,691,976 — all directed to furimazine, hydrofurimazine, and fluorofurimazine compounds used as bioluminescent substrates in Promega’s proprietary NanoLuc® luciferase system. The complaint identified over 50 Aobious product listings spanning Nano-Glo® luciferase assay kits, HiBiT detection systems, NanoBRET® substrates, and in vivo fluorofurimazine reagents.
The case concluded on 15 July 2025 — just 134 days after filing — through a consent judgment signed by Judge Jennifer Choe-Groves. The judgment formally finds Aobious liable for infringement of all four asserted patents, enters a permanent injunction prohibiting Aobious from manufacturing, marketing, using, offering for sale, selling, or importing furimazine, hydrofurimazine, and fluorofurimazine products, and requires Aobious to make monetary payments to Promega per an undisclosed settlement agreement. No appeal rights were reserved by either party.
The 134-day resolution timeline is notably rapid even for consent judgments, suggesting Aobious was unable or unwilling to mount a substantive defence against Promega’s patent portfolio. The absence of defendant’s legal representation on the docket is consistent with an early capitulation or pre-litigation negotiation that converted to a formal court order. The specific monetary terms remain confidential within the settlement agreement, and the public record does not disclose any royalty rates or lump-sum figures agreed upon by the parties.
Filing to Consent Judgment in 134 days
134 days from filing to consent judgment — well below the median D. Del. patent case duration
Consent judgment entered: what the permanent injunction means for both parties
Consent judgment is a court-enforceable settlement
A consent judgment combines a negotiated settlement with judicial authority. Unlike a private settlement, it is entered as a court order, meaning Aobious’s compliance obligations are directly enforceable through contempt proceedings. The court explicitly retained jurisdiction for enforcement purposes. No appeal is permitted under the agreed terms, making the outcome final and immediately binding.
Judicially enforceable outcomePromega secures permanent injunction across all furimazine variants
Promega obtained the strongest available civil remedy: a permanent injunction blocking Aobious from any commercial activity involving furimazine, hydrofurimazine, and fluorofurimazine products. Combined with an undisclosed monetary payment, this outcome validates Promega’s four-patent portfolio and removes a competing supplier from the market. The consent judgment also forecloses future re-entry by Aobious under the same product lines.
Injunction + monetary reliefAobious exits the furimazine substrate market permanently
Aobious conceded infringement across all four asserted patents without mounting a recorded defence. The permanent injunction bars the company from the full commercial lifecycle — manufacture, marketing, sale, offer for sale, and importation — of the named substrate categories. The monetary obligation, while undisclosed, adds financial consequence to the operational shutdown. The no-appeal clause eliminates any future challenge pathway.
Full market exit requiredPromega’s NanoLuc substrate moat is reinforced
The consent judgment signals that Promega’s four-patent cluster covering furimazine-class substrates presents a formidable barrier to third-party suppliers of NanoLuc-compatible reagents. Any life science distributor supplying furimazine, hydrofurimazine, or fluorofurimazine without a Promega licence faces material litigation risk. Research procurement teams and reagent OEMs should conduct FTO analysis before sourcing or distributing these substrate classes.
High licence barrier for competitorsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Promega Corporation | Company | Life science reagent company — holder of US8809529, US10000500, US10669280 & US11691976Search in Eureka ↗ |
| Defendant | Aobious Inc. | Company | Aobious Inc. — distributor of research-use furimazine and luciferase substrate productsSearch in Eureka ↗ |
| Plaintiff counsel | Andrew Mark Moshos | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Anne M. Reynolds | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Bindu Ann George Palapura | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff counsel | David A. Casimir | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff counsel | David Ellis Moore | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff counsel | David W. Staple | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Malisa Dang | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Tyler E. Cragg | Attorney | Counsel for Promega CorporationSearch in Eureka ↗ |
| Plaintiff law firm | Potter Anderson & Corroon, LLP | Law Firm | Representing Promega CorporationSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer Choe-Groves | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s operative language — ‘IT IS HEREBY FOUND, ORDERED, ADJUDGED, AND DECREED’ — carries the same legal weight as a litigated judgment. By expressly finding infringement of all four asserted patents and entering a permanent injunction, the court created a judicially enforceable record that Aobious cannot later relitigate. The no-appeal clause, agreed by both parties, makes this disposition functionally final. The retained jurisdiction clause means any violation of the injunction terms exposes Aobious to contempt sanctions without a new lawsuit.
US8809529, US10000500, US10669280 & US11691976 — NanoLuc furimazine substrate patents
The four asserted patents collectively protect the chemical scaffold and use of furimazine-class coelenterazine analogues as substrates for the NanoLuc® small luciferase reporter system. US8,809,529, filed via application US13/287992, covers the foundational furimazine compound. US10,000,500 (US15/661582) and US10,669,280 (US16/545903) extend to hydrofurimazine variants and additional formulations. US11,691,976 (US16/548214) addresses fluorofurimazine, critical for in vivo imaging applications. Together they represent Promega’s layered IP strategy across the NanoLuc substrate chemistry space.
The NanoLuc platform has become a dominant bioluminescent reporter technology in drug discovery, protein interaction studies, and in vivo imaging. Furimazine and its derivatives are the essential consumable input — without a licence from Promega, third-party suppliers of these substrates face direct infringement exposure. The four-patent cluster, spanning applications filed from 2011 through 2019, provides overlapping coverage that makes substrate design-arounds technically and commercially challenging for any competitor seeking to serve this market segment.
Should you run an FTO against US8809529, US10000500, US10669280 & US11691976?
Any company manufacturing, distributing, or importing furimazine, hydrofurimazine, or fluorofurimazine for research or commercial use should treat Promega’s four-patent cluster as a primary FTO target. The consent judgment in this case confirms Promega’s active enforcement posture. Life science reagent distributors, contract research organisations, and biopharma in vivo imaging teams sourcing NanoLuc-compatible substrates outside Promega’s authorised supply chain carry meaningful litigation exposure.
PatSnap Eureka’s FTO Search Agent can map your substrate chemistry and product specifications against the claim scope of US8,809,529, US10,000,500, US10,669,280, and US11,691,976 in minutes. Eureka’s patent landscape tools also identify design-around opportunities and flag any continuation or divisional applications in Promega’s NanoLuc portfolio that may extend protection beyond these four granted patents. Start your FTO analysis before product launch or procurement commitments.
Run a freedom-to-operate analysis on US10669280B2 to assess your product’s exposure
Run FTO in Eureka →Similar NanoLuc substrate and bioluminescence reagent patent cases
Cases involving furimazine-based luciferase substrate patents and bioluminescence reagent IP enforcement in US district courts, including Delaware.
What this case signals for the bioluminescence reagent IP landscape
Promega’s swift, injunction-backed victory illustrates the depth of its NanoLuc substrate patent estate and its willingness to enforce aggressively.
Four-patent cluster creates near-complete furimazine substrate coverage
Promega’s asserted patents span the original furimazine compound (US8,809,529) through hydro- and fluoro-variants (US10,000,500; US10,669,280; US11,691,976), suggesting a layered prosecution strategy designed to foreclose design-arounds. Any company working in NanoLuc-compatible substrate chemistry should map its product against all four patents before commercialisation.
Absence of defendant counsel signals early commercial capitulation
No defendant law firm appears on the docket, which is consistent with Aobious having accepted Promega’s terms before or shortly after filing. This pattern — immediate consent rather than inter partes review or invalidity counterclaims — suggests Promega’s patents were assessed as difficult to challenge on validity or that commercial exposure made litigation uneconomical for Aobious.
Promega v Aobious — key questions answered
The Delaware District Court entered a consent judgment on 15 July 2025 finding that Aobious Inc. infringed all four asserted Promega patents — US8,809,529, US10,000,500, US10,669,280, and US11,691,976. A permanent injunction was entered barring Aobious from manufacturing, marketing, selling, or importing furimazine, hydrofurimazine, and fluorofurimazine products. Aobious also agreed to make monetary payments per an undisclosed settlement agreement.
Promega asserted four patents: US8,809,529 (foundational furimazine compound), US10,000,500 (furimazine and hydrofurimazine formulations), US10,669,280 (hydrofurimazine substrate variants), and US11,691,976 (fluorofurimazine in vivo substrates). All four relate to coelenterazine-analogue bioluminescent substrates for the NanoLuc® luciferase reporter system used across drug discovery, protein interaction, and in vivo imaging applications.
A consent judgment is a court order that incorporates and enforces the parties’ settlement terms. Unlike a purely private settlement, it has the force of a judicial decree — non-compliance exposes the breaching party to contempt of court. In this case, the court retained jurisdiction specifically to enforce the consent judgment. The underlying settlement agreement is referenced but not publicly filed, so its financial terms remain confidential.
No. The consent judgment expressly states that no appeal shall be taken by any party. Aobious also cannot re-litigate the infringement finding as to its furimazine, hydrofurimazine, and fluorofurimazine products, as the judgment ‘finally concludes and disposes of all claims related to the Asserted Patents’ with respect to those products. However, third parties who were not party to this case could still challenge the patents through inter partes review proceedings at the USPTO.
The permanent injunction prohibits Aobious from any manufacture, marketing, use, offer for sale, sale, and/or importation of furimazine, hydrofurimazine, and fluorofurimazine products. This covers the full commercial lifecycle of the substrate compounds. The injunction applies specifically to Aobious and its activities; it does not bind unrelated third parties, though it signals Promega’s enforcement intent to the broader market.
PatSnap Eureka searches patents and litigation data to answer instantly.